Literature DB >> 22630154

Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages.

Rupinder K Kanwar1, Rajneesh Chaudhary, Takuya Tsuzuki, Jagat R Kanwar.   

Abstract

Inflammation is known to present at all stages of atherosclerotic lesion/plaque development, which often progresses silently for decades, before the occurrence of acute clinical events. Rupture of mature complex plaques with ongoing inflammation can lead to thrombosis, and many adverse acute clinical events such as stroke, myocardial infarction and/or sudden coronary death. Among new-generation noninvasive imaging modalities, molecular MRI with target-specific novel nanoparticulate contrast agents has shown great promise for the visualization of atherosclerosis at the molecular and cellular level in both animals and humans. Considering the key role macrophages play in atherosclerotic inflammation from lesion initiation to plaque rupture, this article reviews the recently engineered magnetic nanoparticulate probes targeting macrophages, their phagocytic activities, surface receptors and molecular products such as neutrophil gelatinase-associated lipocalin. The usefulness of some of these probes as multimodal and drug monitoring agents is also reviewed along with the challenges and future perspectives of the present developments for clinical benefit.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22630154     DOI: 10.2217/nnm.12.46

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  8 in total

1.  Detection of gold nanorods uptake by macrophages using scattering analyses combined with diffusion reflection measurements as a potential tool for in vivo atherosclerosis tracking.

Authors:  Rinat Ankri; Susanne Melzer; Attila Tarnok; Dror Fixler
Journal:  Int J Nanomedicine       Date:  2015-07-09

Review 2.  Superparamagnetic Nanoparticles for Atherosclerosis Imaging.

Authors:  Fernando Herranz; Beatriz Salinas; Hugo Groult; Juan Pellico; Ana V Lechuga-Vieco; Riju Bhavesh; J Ruiz-Cabello
Journal:  Nanomaterials (Basel)       Date:  2014-06-05       Impact factor: 5.076

3.  Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.

Authors:  Suchismita Mohanty; Ketan Yerneni; Johanna Lena Theruvath; Claus Moritz Graef; Hossein Nejadnik; Olga Lenkov; Laura Pisani; Jarrett Rosenberg; Siddhartha Mitra; Alejandro Sweet Cordero; Samuel Cheshier; Heike E Daldrup-Link
Journal:  Cell Death Dis       Date:  2019-01-15       Impact factor: 8.469

Review 4.  Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see.

Authors:  Myra S Cocker; Brian Mc Ardle; J David Spence; Cheemun Lum; Robert R Hammond; Deidre C Ongaro; Matthew A McDonald; Robert A Dekemp; Jean-Claude Tardif; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2012-12       Impact factor: 5.952

5.  Suitability of magnetic nanoparticle immobilised cellulases in enhancing enzymatic saccharification of pretreated hemp biomass.

Authors:  Reinu E Abraham; Madan L Verma; Colin J Barrow; Munish Puri
Journal:  Biotechnol Biofuels       Date:  2014-06-11       Impact factor: 6.040

6.  Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents.

Authors:  Rajneesh Chaudhary; Kislay Roy; Rupinder Kaur Kanwar; Ken Walder; Jagat Rakesh Kanwar
Journal:  J Nanobiotechnology       Date:  2016-01-16       Impact factor: 10.435

7.  Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI.

Authors:  Carlos Tarin; Monica Carril; Jose Luis Martin-Ventura; Irati Markuerkiaga; Daniel Padro; Patricia Llamas-Granda; Juan Antonio Moreno; Isabel García; Nuria Genicio; Sandra Plaza-Garcia; Luis Miguel Blanco-Colio; Soledad Penades; Jesus Egido
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

Review 8.  Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery.

Authors:  Xueqin Zhang; Gangliang Huang
Journal:  Drug Deliv       Date:  2017-12       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.